Foundation Medicine Announces Timing for Fourth Quarter and Year-End 2017 Financial Results and Conference Call

On February 13, 2018 Foundation Medicine, Inc. (NASDAQ:FMI) reported that financial results for the company’s fourth quarter and year ended December 31, 2017 will be released on Wednesday, March 7, 2018 (Press release, Foundation Medicine, FEB 13, 2018, View Source [SID1234523924]). The management team will host a conference call on Wednesday, March 7, 2018, at 4:30 p.m. ET to discuss the company’s financial results and recent developments. The call can be accessed by dialing 1-877-270-2148 (domestic) or 1-412-902-6510 (international) five minutes prior to the start of the call. A passcode is not required to access the live call from either number. A replay of the conference call will be available until March 21, 2018 and can be accessed by dialing 1-412-317-0088 and providing the passcode 10117039.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live, listen-only webcast of the conference call may be accessed by visiting the investors’ section of the company’s website at investors.foundationmedicine.com. A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the company’s website for two weeks following the call.

About Foundation Medicine
Foundation Medicine (NASDAQ:FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit View Source or follow Foundation Medicine on Twitter (@FoundationATCG).

Foundation Medicine is a registered trademark of Foundation Medicine, Inc.